<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Remus EW</submitter><funding>American Heart Association</funding><funding>NINDS NIH HHS</funding><funding>National Institutes of Health</funding><pagination>401-8</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4586408</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>271</volume><pubmed_abstract>The neuroprotective effects of progesterone after ischemic stroke have been established, but the role of progesterone in promoting cerebrovascular repair remains under-explored. Male Sprague-Dawley rats underwent transient middle cerebral artery occlusion (tMCAO) for 90 min followed by reperfusion for 3 days. Progesterone (8 mg/kg/day) was administered intraperitoneally at 1h after initial occlusion followed by subcutaneous injections at 6, 24 and 48 h post-occlusion. Rats were euthanized after 72 h and brain endothelial cell density and macrophage infiltration were evaluated within the cerebral cortex. We also assessed progesterone's ability to induce macrophage migration toward hypoxic/reoxygenated cultured endothelial cells. We found that progesterone treatment post-tMCAO protects ischemic endothelial cells from macrophage infiltration. We further demonstrate that infiltration of monocytes/macrophages can be induced by potent chemotactic factors such as monocyte chemoattractant protein-1 (MCP-1) and the chemokine ligand 1 (CXCL1), secreted by hypoxic/reoxygenated endothelial cells. Progesterone blunts secretion of MCP-1 and CXCL1 from endothelial cells after hypoxia/reoxygenation injury and decreases leukocyte infiltration. The treatment protects ischemic endothelial cells from macrophage infiltration and thus preserves vascularization after ischemic injury.</pubmed_abstract><journal>Experimental neurology</journal><pubmed_title>Progesterone protects endothelial cells after cerebrovascular occlusion by decreasing MCP-1- and CXCL1-mediated macrophage infiltration.</pubmed_title><pmcid>PMC4586408</pmcid><funding_grant_id>NIH UO1 NS062676</funding_grant_id><funding_grant_id>UO1 NS062676</funding_grant_id><funding_grant_id>11SDG5430002</funding_grant_id><funding_grant_id>U01 NS062676</funding_grant_id><pubmed_authors>Remus EW</pubmed_authors><pubmed_authors>Stein DG</pubmed_authors><pubmed_authors>Lyle AN</pubmed_authors><pubmed_authors>Sayeed I</pubmed_authors><pubmed_authors>Won S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Progesterone protects endothelial cells after cerebrovascular occlusion by decreasing MCP-1- and CXCL1-mediated macrophage infiltration.</name><description>The neuroprotective effects of progesterone after ischemic stroke have been established, but the role of progesterone in promoting cerebrovascular repair remains under-explored. Male Sprague-Dawley rats underwent transient middle cerebral artery occlusion (tMCAO) for 90 min followed by reperfusion for 3 days. Progesterone (8 mg/kg/day) was administered intraperitoneally at 1h after initial occlusion followed by subcutaneous injections at 6, 24 and 48 h post-occlusion. Rats were euthanized after 72 h and brain endothelial cell density and macrophage infiltration were evaluated within the cerebral cortex. We also assessed progesterone's ability to induce macrophage migration toward hypoxic/reoxygenated cultured endothelial cells. We found that progesterone treatment post-tMCAO protects ischemic endothelial cells from macrophage infiltration. We further demonstrate that infiltration of monocytes/macrophages can be induced by potent chemotactic factors such as monocyte chemoattractant protein-1 (MCP-1) and the chemokine ligand 1 (CXCL1), secreted by hypoxic/reoxygenated endothelial cells. Progesterone blunts secretion of MCP-1 and CXCL1 from endothelial cells after hypoxia/reoxygenation injury and decreases leukocyte infiltration. The treatment protects ischemic endothelial cells from macrophage infiltration and thus preserves vascularization after ischemic injury.</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015 Sep</publication><modification>2024-10-19T06:19:48.041Z</modification><creation>2019-03-27T01:59:09Z</creation></dates><accession>S-EPMC4586408</accession><cross_references><pubmed>26188381</pubmed><doi>10.1016/j.expneurol.2015.07.010</doi></cross_references></HashMap>